CBUS

Cibus, Inc. (CBUS) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2026. Cibus, Inc. is a plant trait company utilizing gene editing technologies to develop and license traits that improve farming productivity or produce renewable low-carbon plant products. The Company operates as a "smaller reporting company" and is currently in a development phase, not yet earning royalty revenues from commercialized traits. Revenue is primarily derived from collaboration agreements and contract research.

Key Financial Metrics

Note on Debt: The Company carries a significant Royalty Liability - Related Parties of $253.52 million as of June 30, 2026, which includes accrued interest. This liability is non-cash in nature regarding principal repayment but incurs significant interest expense ($18.6 million YTD 2026).

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 36% year-over-year for the six months ended June 30, 2026, driven by collaboration agreements related to Sustainable Ingredients (specifically the Procter & Gamble agreement).
• Expense Reduction: Operating expenses decreased significantly. Research and Development (R&D) expenses fell 28% and Selling, General, and Administrative (SG&A) expenses fell 36% compared to the prior year period. This was due to cost reduction initiatives and the absence of a $21.0 million goodwill impairment charge recorded in Q1 2025.
• Net Loss Improvement: Net loss attributable to stockholders decreased by 40% year-over-year, primarily due to reduced operating expenses and the lack of goodwill impairment.
• Financing Activity: The Company raised approximately $33.4 million in net proceeds from two registered public offerings in January and March 2026. An ATM facility was established in May 2026, though no net proceeds were generated from it in Q2.

Guidance, Outlook, and Risks

• Going Concern Warning: Management has raised substantial doubt about the Company's ability to continue as a going concern within one year. The Company expects its cash on hand ($20.4 million) to fund operations only into early Q1 2027 without additional financing.
• Cash Burn: The Company projects an annual net cash usage run-rate of approximately $35.0 million exiting 2026.
• Strategic Focus: Management is prioritizing Rice herbicide tolerance and Sustainable Ingredients programs. Leadership transitioned in June 2026 with Craig Wichner appointed as CEO.
• Regulatory Environment: The EU approved legislation in June 2026 treating certain gene-edited crops similarly to conventionally bred crops, which may facilitate regulatory pathways for Cibus traits.
• Risks: Key risks include the inability to raise additional capital on acceptable terms, potential dilution from future equity issuances, and the timeline for commercialization of traits.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $20.4 million cash balance against the projected $35 million annual burn rate and the timeline for the next capital raise.
• Royalty Liability: Review the terms of the $253.5 million related-party royalty liability and the impact of the 16.5% effective yield on future interest expenses.
• Commercialization Timeline: Assess the progress of the Rice herbicide tolerance program with Interoc and the Sustainable Ingredients ramp-up with P&G, as these are the primary near-term revenue drivers.
• Capital Markets Access: Monitor the utilization of the $50 million ATM facility and the market's reception to future equity offerings given the current stock price and dilution history.
• Cost Discipline: Confirm that the cost reduction initiatives are sustainable and have not negatively impacted the pace of R&D for priority traits.